Analysis of Dermal Fibroblasts and Immune Cells During Systemic Sclerosis
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The pathophysiology of systemic sclerosis (SSc) is still poorly understood and there are no effective treatments for this disease. SSc is a heterogeneous disease with varying severity. The heterogeneity of fibroblast profiles, observed in other fibrosing pathologies, has never been thoroughly explored in the skin of SSc patients. The immune system, and in particular B lymphocytes, plays a central role in the pathophysiology of SSc. The interactions between B lymphocytes and the cells responsible for excess collagen production, i.e. fibroblasts, are not fully elucidated The main objective is to analyze the heterogeneity of fibroblasts and infiltrating immune cells as well as their molecular signature in the skin of patients with SSc
Eligibility Criteria
Inclusion Criteria: * Man or woman over 18 years of age * With a systemic sclerosis meeting the ACR-EULAR 2013 criteria Having signed an informed consent * Being insured Exclusion Criteria: * Syndrome of overlap with another connective tissue disease according to the international diagnostic criteria * Immunosuppressive treatment within 12 months * Dosage of current corticosteroid therapy ≥10mg/d * Protected minors or adults * Pregnant or breastfeeding women * Deprived of their liberty * Persons in emergency situations * Persons who have refused or are unable to give informed consent